Nonviral Platforms Streamline Gene Therapy Delivery genengnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from genengnews.com Daily Mail and Mail on Sunday newspapers.
CAMBRIDGE, Mass. (BUSINESS WIRE) Vesigen Therapeutics, Inc., a biotechnology company developing a novel non-viral delivery platform for gene editors, RNA, and protein-based therapeutics, today announced eight data presentations at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting being held M.
Share this article
Share this article
CAMBRIDGE, Mass., March 16, 2021 /PRNewswire/ Vesigen Therapeutics, Inc., a biotechnology company pioneering a novel extracellular vesicle delivery technology to develop transformative therapeutics, today announced that the United States Patent and Trademark Office has issued U.S. Patent No. 10,945,954 entitled ARRDC1-Mediated Microvesicles (ARMMs) and Uses Thereof . This patent, exclusively licensed to Vesigen from Harvard University, broadly covers many of the drug delivery features of any ARRDC1-mediated microvesicles (ARMMs).
This patent covers ARMMs compositions containing an enzymatic payload. Important enzymes include those needed in enzyme replacement therapy as well as those intended to create a therapeutic function.